EKSO icon

Ekso Bionics

3.84 USD
-0.03
0.78%
At close Jun 13, 4:00 PM EDT
Pre-market
3.78
-0.06
1.56%
1 day
-0.78%
5 days
-10.90%
1 month
-42.77%
3 months
-44.35%
6 months
-54.82%
Year to date
-58.89%
1 year
-77.35%
5 years
-93.23%
10 years
-99.57%
 

About: Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.

Employees: 66

0
Funds holding %
of 7,296 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

16% more funds holding

Funds holding: 32 [Q4 2024] → 37 (+5) [Q1 2025]

3.11% less ownership

Funds ownership: 18.36% [Q4 2024] → 15.25% (-3.11%) [Q1 2025]

38% less capital invested

Capital invested by funds: $2.46M [Q4 2024] → $1.53M (-$939K) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$60
1,463%
upside
Avg. target
$60
1,463%
upside
High target
$60
1,463%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
1,463%upside
$60
Buy
Maintained
6 May 2025

Financial journalist opinion

Neutral
GlobeNewsWire
3 weeks ago
Ekso Bionics Announces New Effective Date of Reverse Stock Split
SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on June 2, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split.
Ekso Bionics Announces New Effective Date of Reverse Stock Split
Neutral
GlobeNewsWire
3 weeks ago
Ekso Bionics Announces Reverse Stock Split
SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on May 27, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split.
Ekso Bionics Announces Reverse Stock Split
Neutral
GlobeNewsWire
1 month ago
Ekso Bionics Accepted into NVIDIA Connect Program
Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation
Ekso Bionics Accepted into NVIDIA Connect Program
Neutral
Seeking Alpha
1 month ago
Ekso Bionics Holdings, Inc. (EKSO) Q1 2025 Earnings Call Transcript
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Stephen Kilmer - IR Jerome Wong - Chief Financial Officer Scott Davis - Chief Executive Officer Conference Call Participants Ben Haynor - Lake Street Capital Markets Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics First Quarter 2025 Financial Results Conference Call.
Ekso Bionics Holdings, Inc. (EKSO) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Ekso Bionics (EKSO) Reports Q1 Loss, Misses Revenue Estimates
Ekso Bionics (EKSO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.20 per share a year ago.
Ekso Bionics (EKSO) Reports Q1 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Ekso Bionics Reports First Quarter 2025 Financial Results
SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025.
Ekso Bionics Reports First Quarter 2025 Financial Results
Neutral
GlobeNewsWire
1 month ago
Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow
SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments.
Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow
Neutral
GlobeNewsWire
1 month ago
Bionic P&O Chosen as First Distributor of Ekso Indego® Personal Within the Orthotics & Prosthetics Industry
SAN RAFAEL, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has named Bionic Prosthetics & Orthotics Group LLC (“Bionic P&O”), a leading national provider of prosthetic and orthotic solutions, as a non-exclusive Ekso Indego® Personal device distributor.
Bionic P&O Chosen as First Distributor of Ekso Indego® Personal Within the Orthotics & Prosthetics Industry
Neutral
Seeking Alpha
3 months ago
Ekso Bionics Holdings, Inc. (EKSO) Q4 2024 Earnings Call Transcript
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Stephen Kilmer - IR Jerome Wong - Chief Financial Officer Scott Davis - Chief Executive Officer Conference Call Participants Li Chen - H.C. Wainwright Ben Haynor - Lake Street Capital Operator Greetings, and welcome to the Ekso Bionics Fourth Quarter 2024 Financial Results Conference Call.
Ekso Bionics Holdings, Inc. (EKSO) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
3 months ago
Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results
SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024.
Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results
Charts implemented using Lightweight Charts™